Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Home / Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Estimated reading time: < 1 min

Condition

Advanced Cancer

Estimated Enrollment: 1100

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 3475-158|2015-002067-41|163196

Study First Received: December 9, 2015

Last Updated: February 23, 2017

Estimated Primary Completion Date: September 2017

 

Primary Outcome Measures:

Objective Response Rate (ORR)

Sponsors and Collaborators:

Merck Sharp & Dohme Corp.

Website Link: https://ClinicalTrials.gov/show/NCT02628067

Was this article helpful?
Dislike 0
Views: 3